Identification of a seven-cell cycle signature predicting overall survival for gastric cancer

Lian-Qun Zhang1, Sheng-Li Zhou2, Jun-Kuo Li3, Pei-Nan Chen4, Xue-Ke Zhao5, Li-Dong Wang5, Xiu-Ling Li1, Fu-You Zhou3

1Department of Gastroenterology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou 450003, Henan, China
2Department of Pathology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou 450003, Henan, China
3Department of Thoracic Surgery, Anyang Tumor Hospital, Anyang 455000, Henan, China
4Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China
5State Key Laboratory of Esophageal Cancer Prevention and Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450003, Henan, China

Correspondence to: Lian-Qun Zhang, Fu-You Zhou; email: Zhanglianqun2010@126.com, https://orcid.org/0000-0002-5638-6016; ayzhoufuyou@163.com, https://orcid.org/0000-0002-6548-4099

Keywords: gastric cancer, cell cycle, prognostic model, TCGA, GEO

Received: January 15, 2022 Accepted: April 25, 2022 Published: May 10, 2022

ABSTRACT

While genetic alterations in several regulators of the cell cycle have a significant impact on the gastric carcinogenesis process, the prognostic role of them remains to be further elucidated. The TCGA-STAD training set were downloaded and the mRNA expression matrix of cell cycle genes was extracted and corrected for further analysis after taking the intersection with GSE84437 dataset. Differentially expressed mRNAs were identified between tumor and normal tissue samples in TCGA-STAD. Univariate Cox regression analysis and lasso Cox regression model established a novel seven-gene cell cycle signature (including GADD45B, TFDP1, CDC6, CDC25A, CDC7, SMC1A and MCM3) for GC prognosis prediction. Patients in the high-risk group shown significantly poorer survival than patients in the low-risk group. The signature was found to be an independent prognostic factor for GC survival. Nomogram including the signature shown some clinical net benefit for overall survival prediction. The signature was further validated in the GSE84437 dataset. In tissue microarray, CDC6 and MCM3 protein expression were significant differences by the immunohistochemistry-based H-score between tumor tissues and adjacent tissues, and CDC6 is an independent prognostic factor for GC. Interestingly, our GSEA revealed that low-risk patients were more related to cell cycle pathways and might benefit more from therapies targeting cell cycle. Our study identified a novel robust seven-gene cell cycle signature for GC prognosis prediction that may serve as a beneficial complement to clinicopathological staging. The signature might provide potential biomarkers for the application of cell cycle regulators to therapies and treatment response prediction.

INTRODUCTION

The mammalian cell cycle is a highly structured and regulated process that ensures the duplication of the genetic material and cell division. Cell cycle regulation involves both mechanisms that govern growth regulation and genetic integrity. Cancer is characterized by abnormal cell cycle activity, possibly because of upstream signaling pathway gene mutations or mutations in the genes that encode cyclins. Genetic changes in several cell cycle regulators have a key influence on the pathogenetic process of gastric cancer (GC) [1]. Studies
have shown that cell cycle regulators are potential GC prognosis biomarkers of great clinical value [2], and targeting cell cycle regulators in GC treatment has also increasingly attracted attention [3].

Among the five most common cancers worldwide, GC is the third major cause of cancer mortality [4]. Despite surgical and adjuvant therapies, the prognosis of GC patients remains poor, and patients’ 5-year overall survival rate is below 25% [5]. Until now, the prediction of prognosis has primarily depended on histopathologic diagnosis and neoplasm staging systems. However, many patients in the progressive stage who have similar clinicopathologic features show great differences in prognosis.

Although much effort has been spent developing optimum tools for the prediction of GC prognosis, no consensus has been reached as to the best method. In most of the existing literature, clinical baseline characteristics (e.g., tumor size, lymphonodus count, and lymphatic vascular space invasion) and unimolecular biomarkers (e.g., CD44 [6], PPAR γ [7], IL-13Rα2 [8], HDAC6 [9]) are utilized to construct prognostic models. Nevertheless, the predictive power of monogenic biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent development singenomic sequencing, the integration of prognosis - biomarkers is insufficient. Based on recent developmentsingeno...
Table 1. Clinical features n (%) of GC patients with OS longer than 30 days.

| Parameters                           | TCGA-STAT patients with mRNA expression data (n = 334) | GSE84437 patients with mRNA expression data (n = 431) | Chinese GC patients with immunohistochemical data (n = 232) |
|--------------------------------------|---------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------|
| Gender                               | Male 216 (64.67)                                       | 294 (68.21)                                             | 161 (69.40)                                                 |
|                                      | Female 118 (35.33)                                    | 137 (31.79)                                             | 71 (30.60)                                                  |
| Age (mean ± s.d.)                    | 65.17 ± 10.22                                         | 60.02 ± 11.58                                           | 58.09 ± 12.18                                              |
| pTNM                                 | I 44 (13.17)                                           | -                                                       | 32 (13.79)                                                  |
|                                      | II 106 (31.74)                                         | -                                                       | 80 (34.48)                                                  |
|                                      | III 137 (41.02)                                        | -                                                       | 98 (42.24)                                                  |
|                                      | IV 33 (9.88)                                           | -                                                       | 22 (9.48)                                                   |
|                                      | unknow 14 (4.19)                                       | -                                                       | -                                                           |
| T-stage                              | 1 14 (4.19)                                            | 11 (2.55)                                               | 26 (11.21)                                                  |
|                                      | 2 72 (21.56)                                           | 38 (8.82)                                               | 27 (11.64)                                                  |
|                                      | 3 156 (46.71)                                          | 92 (21.35)                                              | 79 (34.05)                                                  |
|                                      | 4 88 (26.35)                                           | 290 (67.29)                                             | 100 (43.10)                                                 |
|                                      | X 4 (1.20)                                             | -                                                       | -                                                           |
| N-stage                              | 0 98 (29.34)                                           | 80 (18.56)                                              | 76 (32.76)                                                  |
|                                      | 1 90 (26.95)                                           | 187 (43.39)                                             | 49 (21.12)                                                  |
|                                      | 2 68 (20.36)                                           | 132 (30.63)                                             | 47 (20.26)                                                  |
|                                      | 3 67 (20.06)                                           | 32 (7.42)                                               | 60 (25.86)                                                  |
|                                      | X 11 (3.29)                                            | -                                                       | -                                                           |
| M-stage                              | 0 300 (89.82)                                          | -                                                       | 210 (90.52)                                                 |
|                                      | 1 22 (6.59)                                            | -                                                       | 22 (9.48)                                                   |
|                                      | X 12 (3.59)                                            | -                                                       | -                                                           |
| Grade                                | G1 9 (2.69)                                            | -                                                       | 2 (0.86)                                                    |
|                                      | G2 117 (35.03)                                         | -                                                       | 53 (22.84)                                                  |
|                                      | G3 199 (59.58)                                         | -                                                       | 177 (76.29)                                                 |
|                                      | GX 9 (2.69)                                            | -                                                       | -                                                           |
| Vessel carcinoma embolus             | Yes -                                                  | -                                                       | 30 (12.93)                                                  |
|                                      | No -                                                   | -                                                       | 202 (87.07)                                                 |
| Vital status                         | Alive 220 (65.87)                                      | 224 (51.97)                                             | 137 (59.05)                                                 |
|                                      | Dead 124 (37.13)                                       | 207 (48.03)                                             | 95 (40.95)                                                  |

GC, gastric cancer; mRNA, messenger RNA; OS, overall survival; TCGA, the Cancer Genome Atlas.

our results, the nomogram model better predicted survival prognosis than the clinical model for GC.

External immunohistochemical validation based on protein levels

Protein levels of CDC6 and MCM3 from 234 Chinese patients with GC were obtained using immunohistochemistry. We found that the expression in tumor tissues of these proteins was significantly higher than that in nontumor tissues (P < 0.01). Among the patients, data from 232 Chinese GC patients with OS longer than 30 days (Table 1) were included in univariate and multivariate Cox regression analyses. The results showed that TNM staging were associated with prognosis (Table 1). Furthermore, CDC6 was an independent
prognostic factor in GC patients with T\textsubscript{1-3}N\textsubscript{1-2}M\textsubscript{0} staging and no vascular tumor thrombus as presented in the 7\textsuperscript{th} version of the ACJJ \(P<0.05\) (Figure 4).

**Gene set enrichment analysis**

Through gene set enrichment analysis (GSEA) of the differentially expressed genes from the TCGA-STAD dataset, we found that KEGG cell cycle pathways were enriched in the low-risk group \(P<0.001\) and false discovery rate (FDR)<0.001 (Figure 5).

**DISCUSSION**

In this study, we included cell cycle-related genes associated with GC to explore their potential as prognostic factors for GC. We identified seven prognosis-related cell cycle genes and established a risk prediction model. For GC patients with high- and low-risk scores, we observed different survival rates. Additionally, a nomogram created by combining clinical factors with our prognostic model performed even better in predicting the survival prognosis of GC patients, with verification in a second dataset.

As a heterogeneous disease, the development of GC is a long and multistep process. Because of the gradual accumulation of genetic mutations, carcinogenesis and anti-cancer pathway imbalances eventually give rise to GC [12]. With progress in medical technology, the morbidity and mortality of GC have both declined. However, the current prognosis of GC patients is not optimistic [13].

In cancer, abnormal activity of various cyclins leads to uncontrollable tumor cell proliferation. In the literature, it has been reported that cell cycle regulators are related to the prognosis of GC patients. For instance, in gastric adenocarcinoma tissues, downregulated expression of the protein p27 is correlated with advanced tumors [14]. Among poorly differentiated tumors, the expression

---

**Figure 1.** Risk score analysis and Kaplan–Meier survival analysis for seven differentially expressed genes in GC. (A, B) The distribution of risk score and patient’s survival time, as well as status for TCGA-STAD (A) and GSE84437 (B). (C, D) Heatmap of the autophagy-associated gene expression profiles in prognostic signature for TCGA-STAD (C) and GSE84437 (D). (E, F) Kaplan-Meier curves of seven differentially expressed genes from TCGA-STAD (E) and GSE84437 (F).
levels of p27 and CCND1 were elevated and were shown to be negative prognostic factors for patient survival [15]. Overexpression of the proteins CCND1 and CCND2 is associated with the short OS of GC patients [16]. Furthermore, binding of cyclin E and cyclin-dependent kinase 2 promotes the transition of the cell cycle from stage G1 to stage S. The prognosis of GC patients positive for cyclin E is poor; combining cyclin E

Figure 2. Cell cycle-associated genes significantly correlated with survival rates of GC patients. (A–D) Forrest plots of univariate and multivariate Cox regression analysis (E, F) OS sensitivity and specificity analysis for the risk score determined by the expression of seven genes in TCGA-STAD (E) and GSE84437 (F) based on ROC analysis.
overexpression with p53 expression was able to differentiate patients with poor prognosis [17, 18]. Recently, bioinformatics methods were used to confirm that five G2/M checkpoint-related genes (i.e., MARCKS, CCNF, MAPK14, INSENP, and CHAF1A) were related to the OS of GC patients [19]. Nevertheless, these studies have not established a prognostic model for GC prediction based on the genetic characterization of genes associated with the cell cycle.

In recent years, mRNA expression has been investigated on the basis of whole-genome sequencing data [20]. Using these data, studies have investigated TP53 mutations and mutations in autophagy-related genes to construct prognostic models, showing that these models can successfully predict GC prognosis [10, 11]. In this study, CDC6 and MCM3 showed the greatest differences and were most strongly correlated with prognosis in the TCGA dataset. MCM3 falls into a family of six highly conserved minichromosomal maintenance proteins, MCM2–MCM7. These proteins are critical for ensuring that eucaryon DNA replication takes place only once in each cell cycle. Additionally, MCM3 also serves as a helicase to facilitate replication extension. At an advanced stage of M1, CDT1 and CDC6 recruit iso-hexamer MCM2–MCM7 complexes and load them onto an origin of replication, producing prereplication complexes [21]. Additionally, CDC6 is an important cell cycle regulator [22]. By assembling prereplication complexes, it plays an essential role in maintaining chromosome integrity [23, 24]. Moreover, CDC6 is also closely related to tumorigenesis. Besides

Figure 3. Building and validation of the nomogram predicting the OS of GC patients in TCGA-STAD and GSE84437 datasets. (A, B) Nomogram based on four independent prognostic factors of GC. (C, D) Calibration map for internal validation of the nomogram. (E–J) Time-dependent ROC curves of the nomogram for comparing the 1, 2, and 3 year OS of GC patients. Data in Figures (E, G, I) are derived from TCGA data, whereas those in Figures (F, H, J) are from the GSE84437 array.
Figure 4. Protein expression levels of CDC6 and MCM3 in Chinese GC patients by immunohistochemistry (IHC). CDC6 significantly correlated with survival rates of GC patients with stratified analysis. HE-stained sections (A) and IHC staining of CDC6 in nontumor tissues: H-SCORE 181.1 (B); HE-stained sections (C) and IHC staining of CDC6 in tumor tissues: H-SCORE 169.8 (D); HE-stained sections (E) and IHC staining of MCM3 in nontumor tissues: H-SCORE 52.7 (F); HE-stained sections (G) and IHC staining of MCM3 in tumor tissues: H-SCORE 156.1 (H); Magnification: 400×. (I–L) Forrest plots of univariate and multivariate Cox regression analysis.

Figure 5. KEGG pathways in GSEA significantly enriched among differentially expressed genes from the TCGA data.
playing a role in cancer-related pathways by regulating the expression of certain oncogenes and cancer suppressor genes such as KRAS [25], CDC6 promotes cancer progression as it is positively regulated by associated noncoding RNAs (e.g., IncRNA-CDC6) [26]. Furthermore, the expression of CDC6 is upregulated in multiple tumor types [27, 28]; CDC6 serves as a prognostic biomarker of breast carcinoma [29], colorectal cancer [30], pancreatic cancer [31], and other cancers. CDC6 knockdown has been shown to inhibit the growth and invasion of GC cells. Transfection of pS-CDC6 knocked down CDC6 expression in the GC cell lines BGC823 and SGC7901. MTT assay showed that transfection of pS-CDC6 markedly inhibited cell proliferation in BGC823 and SGC7901 cells. Transwell assay revealed that pS-CDC6 transfection inhibited the invasive capacities of BGC823 and SGC7901 cells. This likely be due to CDC6 knockdown promoting the apoptosis of these cells [32]. Among 232 Chinese GC patients, validation through immunohistochemical methods showed that the protein levels of CDC6 and MCM3 in tumor and nontumor tissues had significantly different histochemistry scores (H-scores; see Methods).

Additionally, we showed that CDC6 is an independent prognostic factor for GC with stratified analysis. Finally, via KEGG enrichment analysis, we showed that multivariate model of cell cycle genes was constructed via lasso regression. In the lasso regression model, genes correlated with the OS of individuals included in the TCGA-STAD dataset. According to the hazard ratio of each gene and P-values obtained using the Wald test, P<0.05 was adopted as the threshold to select genes that were significantly correlated with the survival of GC patients. Based on the “glmnet” package in R [33, 34], a multivariate model of cell cycle genes was constructed via lasso regression. In the lasso regression model, genes with nonzero coefficients were selected to calculate risk scores by the following equation: risk score=∑nj=1 Coefj*Xj, where Coefj stands for the coefficient and Xj for the relative expression level of each cell cycle gene [35]. All TCGA patients were divided into two groups (i.e., a high-risk group and a low-risk group) depending on the median risk score. Similar to the TCGA dataset, the same formula was used to determine the risk scores in the GEO dataset. We then calculated Kaplan–Meyer survival curves and used the log-rank test to clarify the statistical significance of the difference in OS between the two groups. Clinical information (e.g., age, sex, T-staging, and N-staging) was then extracted from the TCGA-STAD and GSE84437 datasets. These factors were tested for their impact on prognosis with univariate and multivariate Cox regression analyses. Any factor with a P<0.05 was deemed statistically significant. Moreover, ROC curves were also calculated to verify the predictive value of the model.

Conclusions

We constructed a prognostic model involving seven cell cycle genes based on GC data from TCGA and GEO. Combining the proposed prognostic model with a nomogram of clinical pathology, a higher survival prognosis prediction ability can be achieved. According to our findings, the proposed prognostic model may promote individualized diagnosis and treatment of GC patients and thus further improve the prognosis of these patients.

MATERIALS AND METHODS

Gene expression data

On the TCGA website, we downloaded RNA sequencing and clinical data involving 375 GC tissues and 32 nontumor tissues from the STAD dataset. Subsequently, 125 cell cycle-related genes were obtained from the KEGG database, and GSE84437 data were downloaded from the GEO database. These datasets were used for further analysis after they were corrected by the “batchType” correction model in the SVA4.04R software package.

Differentially expressed cell cycle genes in GC

Using the “limma” package in R, 375 tumor samples and 32 normal tissue samples from TCGA were subjected to differential expression analysis for cell cycle genes. Differentially expressed genes were selected with an FDR of <0.05 and log fold-change of >0.5.

Prognostic gene model

Univariate Cox proportional hazards regression analysis was conducted to select cell cycle genes significantly correlated with the OS of individuals included in the TCGA-STAD dataset. According to the hazard ratio of each gene and P-values obtained using the Wald test, P<0.05 was deemed statistically significant. To understand the specific mechanism and biological functions of cell cycle genes on prognosis, further investigation is needed.

Nomogram-based prediction model

Survival data from the patients were combined with their age, T-staging, N-staging, and risk scores to build a nomogram using the “rms” package in R. Subsequently, calibration curves were calculated to evaluate the consistency between the actual and predicted survival rates. Furthermore, a C-index ranging from 0.5 to 1.0 was
calculated to assess the performance of the prognosis prediction model. The AUC was used to evaluate the sensitivity and specificity of the model.

**Immunohistochemical evaluation of protein expression levels of cell cycle genes**

Two hundred fifty tumor tissues and 144 nontumor tissues were derived from 250 Chinese patients affected by GC. From the TCGA database, CDC6 and MCM3, which were most closely correlated with prognosis, were selected for validation based on their protein levels. The H-score is used to evaluate immunohistochemical conditions. In detail, the number of positive cells on each slide and their staining intensity are converted into values as a semiquantitative measure of the amount of histological staining. H-Score \( \text{H-Score}=\sum p_i \times i \) = (percentage of weak intensity cells \( \times 1 \)) + (percentage of moderate intensity cells \( \times 2 \)) + (percentage of strong intensity cells \( \times 3 \)), where \( p_i \) represents the proportion of positive cells and \( i \) is the staining intensity. The H-score has a range of 0–300. The greater the value is, the greater the staining intensity of positive cells will be [36, 37].

**Gene set enrichment analyses**

Regarding the differentially expressed genes in the TCGA-STAD array between the high- and low-risk groups, GSEA was used to identify enriched pathways [38, 39]. \( P<0.05 \) and \( \text{FDR}<0.25 \) were considered statistically significant.

**Statistical analysis**

All statistical analyses were conducted in R software (Version 4.0.4; [https://www.R-project.org](https://www.R-project.org)). The correlation between the risk scores and clinical features was investigated using the \( \chi^2 \) test. Besides drawing Kaplan–Meier curves, a log-rank test was conducted to test intergroup differences in OS. Univariate and multivariate Cox proportional risk regression analyses were conducted to determine the association between the risk score and OS. The AUC was calculated as a measure of the prediction accuracy of the prognostic models. \( P<0.05 \) was used to signify statistically significant results.

**AUTHOR CONTRIBUTIONS**

L-Q Z, L-D W and F-Y Z contributed design and idea of the study. S-L Z, J-K L, X-K Z and L-Q Z contributed collection and procession of clinical data. S-L Z and J-K L performed experiments. L-Q Z, P-N C and S-L Z performed the data analysis and interpreted the results. S-L Z, L-Q Z, X-L L and F-Y Z wrote the manuscript. All authors contributed to the article and approved the submitted version.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

**FUNDING**

This work was supported by grants from the Postdoctoral Foundation of Zhengzhou University and Doctoral Research Initiation Fund of Henan Provincial people’s Hospital.

**REFERENCES**

1. Choi RS, Lai WYX, Lee LTC, Wong WLC, Pei XM, Tsang HF, Leung JJ, Cho WCS, Chu MKM, Wong EYL, Wong SCC. Current and future molecular diagnostics of gastric cancer. Expert Rev Mol Diagn. 2019; 19:863–74. [https://doi.org/10.1080/14737159.2019.1660645](https://doi.org/10.1080/14737159.2019.1660645). PMID: 31448971

2. Machlowska J, Maciejewski R, Sitarz R. The Pattern of Signatures in Gastric Cancer Prognosis. Int J Mol Sci. 2018; 19:1658. [https://doi.org/10.3390/ijms19061658](https://doi.org/10.3390/ijms19061658). PMID: 29867026

3. Min A, Kim JE, Kim YJ, Lim JM, Kim S, Kim JW, Lee KH, Kim TY, Oh DY, Bang YJ, Im SA. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. Cancer Lett. 2018; 430:123–32. [https://doi.org/10.1016/j.canlet.2018.04.037](https://doi.org/10.1016/j.canlet.2018.04.037). PMID: 29729292

4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108. [https://doi.org/10.3322/caac.21262](https://doi.org/10.3322/caac.21262). PMID: 25651787

5. Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014; 63:236–43. [https://doi.org/10.1136/gutjnl-2013-304531](https://doi.org/10.1136/gutjnl-2013-304531). PMID: 23580779

6. Szczepanik A, Sierzeja M, Drabik G, Pituch-Noworolska A, Kołodziejczyk P, Zembala M. CD44+ cytokeratin-positive tumor cells in blood and bone marrow are associated with poor prognosis of patients with gastric cancer. Gastric Cancer. 2019; 22:264–72.
7. Cho SJ, Kook MC, Lee JH, Shin JY, Park J, Bae YK, Choi IJ, Ryu KW, Kim YW. Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer. Int J Cancer. 2015; 136:810–20. https://doi.org/10.1002/ijc.29056 PMID:24976296

8. Lin C, Liu H, Zhang H, He H, Li H, Shen Z, Qin J, Qin X, Xu J, Sun Y. Interleukin-13 receptor α2 is associated with poor prognosis in patients with gastric cancer after gastrectomy. Oncotarget. 2016; 7:49281–8. https://doi.org/10.18632/oncotarget.10297 PMID:27351230

9. He Q, Li G, Wang X, Wang S, Hu J, Yang L, He Y, Pan Y, Yu D, Wu Y. A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer. Cell Physiol Biochem. 2017; 42:1326–35. https://doi.org/10.1159/000478961 PMID:28700998

10. Nie K, Zheng Z, Wu Y, Liu H, Zhang H, He H, Li H, Shen Z, Qin J, Qin X, Xu J, Sun Y. Interleukin-13 receptor α2 is associated with poor prognosis in patients with gastric cancer after gastrectomy. Oncotarget. 2016; 7:49281–8. https://doi.org/10.18632/oncotarget.10297 PMID:27351230

11. Chen L, Ma G, Wang P, Dong Y, Liu Y, Zhao Z, Guo J, Li Q, Cheng J, Pan J, Jiang X, Jiang K, et al. Construction and validation of a TP53-associated immune prognostic model for gastric cancer. Genomics. 2020; 112:4788–95. https://doi.org/10.1016/j.ygeno.2020.08.026 PMID:32858135

12. Molina-Castro S, Pereira-Marques J, Figueiredo C, Machado JC, Varon C. Gastric cancer: Basic aspects. Helicobacter. 2017 (Suppl 1); 22:e12412. https://doi.org/10.1111/hel.12412 PMID:28700998

13. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118:3030–44. https://doi.org/10.1002/ijc.21731 PMID:16404738

14. Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P, Lise M. Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol. 2002; 81:167–75. https://doi.org/10.1002/jso.10172 PMID:12451619

15. Shan YS, Hsu HP, Lai MD, Hung YH, Wang CY, Yen MC, Chen YL. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncol Lett. 2017; 14:4517–26. https://doi.org/10.3892/ol.2017.6736 PMID:28943959

16. Ding ZY, Li R, Zhang QJ, Wang Y, Jiang Y, Meng QY, Xi QL, Wu GH. Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis. Cancer Med. 2019; 8:2717–29. https://doi.org/10.1002/cam4.2152 PMID:30950241

17. Alsina M, Landolfi S, Aura C, Caci K, Jimenez J, Prudkin L, Castro S, Moreno D, Navalpoto B, Tabernero J, Scaltriti M. Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. Ann Oncol. 2015; 26:438–9. https://doi.org/10.1093/annonc/mdu535 PMID:25403579

18. Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res. 2005; 11:1447–53. https://doi.org/10.1158/1078-0432.CCR-04-1730 PMID:15746045

19. Zhao L, Jiang L, He L, Wei Q, Bi J, Wang Y, Yu L, He M, Zhao L, Wei M. Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. J Cell Physiol. 2019; 234:6350–60. https://doi.org/10.1002/jcp.27365 PMID:3028991

20. Dai J, Li ZX, Zhang Y, Ma JL, Zhou T, You WC, Li WQ, Pan KF. Whole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival. Clin Transl Gastroenterol. 2019; 10:e00004. https://doi.org/10.14309/ctg.0000000000000004 PMID:30702489

21. Hyrien O, Marheineke K, Goldar A. Paradoxes of eukaryotic DNA replication: MCM proteins and the random completion problem. Bioessays. 2003; 25:116–25. https://doi.org/10.1002/bies.10208 PMID:12539237

22. Kim GS, Lee I, Kim JH, Hwang DS. The Replication Protein Cdc6 Suppresses Centrosome Over-Duplication in a Manner Independent of Its ATPase Activity. Mol Cells. 2017; 40:925–34. https://doi.org/10.14348/molcells.2017.0191 PMID:29237113

23. Borlado LR, Méndez J. Cdc6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis. 2008; 29:237–43. https://doi.org/10.1093/carcin/bgm268 PMID:18048387

24. Teixeira LK, Reed SI. Cdc6: Skin in the carcinogenesis game. Cell Cycle. 2016; 15:313. https://doi.org/10.1080/15384101.2015.1131528 PMID:26694635

25. Rossi E, Klersy C, Manca R, Zuffardi O, Solcia E. Correlation between genomic alterations assessed
by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. Hum Pathol. 2011; 42:1937–45. https://doi.org/10.1016/j.humpath.2011.02.016 PMID:21676433

26. Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, Liu Y, Zhang N, Yang Q. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2019; 234:9105–17. https://doi.org/10.1002/jcp.27587 PMID:30362551

27. Kim YH, Byun YJ, Kim WT, Jeong P, Yan C, Kang HW, Kim YJ, Lee SC, Moon SK, Choi YH, Yun SJ, Kim WJ. CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. J Korean Med Sci. 2018; 33:e303. https://doi.org/10.3346/jkms.2018.33.e303 PMID:30450027

28. Deng Y, Jiang L, Wang Y, Xi Q, Zhong J, Liu J, Yang S, Liu R, Wang J, Huang M, Tang C, Su M. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer. Pathol Res Pract. 2016; 212:239–46. https://doi.org/10.1016/j.prp.2015.09.014 PMID:26920249

29. Mahadevappa R, Neves H, Yuen SM, Bai Y, McCrudden CM, Yuen HF, Wen Q, Zhang SD, Kwok HF. The prognostic significance of Cdc6 and Cdt1 in breast cancer. Sci Rep. 2017; 7:985. https://doi.org/10.1038/s41598-017-00998-9 PMID:28428557

30. Hu Y, Wang L, Li Z, Wan Z, Shao M, Wu S, Wang G. Potential Prognostic and Diagnostic Values of CDC6, CDC45, ORC6 and SNHG7 in Colorectal Cancer. Onco Targets Ther. 2019; 12:11609–21. https://doi.org/10.2147/OTT.S231941 PMID:3021241

31. Yan X, Wan H, Hao X, Lan T, Li W, Xu L, Yuan K, Wu H. Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. Cancer Manag Res. 2018; 12:273–83. https://doi.org/10.2147/CMAR.S185205 PMID:30643453

32. Zhao B, Zhang J, Chen X, Xu H, Huang B. Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer. Arch Med Sci. 2013; 15:498–503. https://doi.org/10.5114/ams.2018.73315 PMID:30899303

33. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33:1–22. PMID:20808728

34. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007; 26:5512–28. https://doi.org/10.1002/sim.3148 PMID:18058845

35. Kidd AC, McGettrick M, Tsim S, Halligan DL, Bylesjo M, Blyth KG. Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. BMJ Open Respir Res. 2018; 5:e000240. https://doi.org/10.1136/bmjresp-2017-000240 PMID:29468073

36. Maclean A, Bunni E, Makrydima S, Withington A, Kamal AM, Valentinj AJ, Hapangama DK. Fallopian tube epithelial cells express androgen receptor and have a distinct hormonal responsiveness when compared with endometrial epithelium. Hum Reprod. 2020; 35:2097–106. https://doi.org/10.1093/humrep/deaa177 PMID:32876325

37. Dogan S, Vasudevaraja V, Xu B, Serrano J, Ptashkin RN, Jung HJ, Chiang S, Junghbluth AA, Cohen MA, Ganly I, Berger MF, Momeni Boroujeni A, Ghossein RA, et al. DNA methylation-based classification of sinonasal undifferentiated carcinoma. Mod Pathol. 2019; 32:1447–59. https://doi.org/10.1038/s41379-019-0285-x PMID:31186531

38. Mootha VK, Lindgren CM, Eriksson FF, Subramanian A, Sihag S, Lehar J, Puigserver P, Karlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34:267–73. https://doi.org/10.1038/ng1180 PMID:12808457

39. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102:15545–50. https://doi.org/10.1073/pnas.0506580102 PMID:16199517